News / Events

Boston, MA, May 1st, 2014 - ActeaVentures GmbH is pleased to welcome Michael Palfreyman Ph.D., D.Sc. as Associate Partner. Dr. Palfreyman joins ActeaVentures following a 40 years career within the pharmaceutical and biotech industry in which he held Senior Management positions in R&D and Business Development

at Marion Merrell Dow, Scriptgen Pharmaceuticals, Psychiatric Genomics, EnVivo Pharmaceuticals, Chemical Diversity, Amakem and Ophthakem. Most recently he acted as Senior R&D Diligence and Scientific Adviser at Torrey Pines Investment, Inc.. Dr. Palfreyman will head the Boston, MA, office of ActeaVentures.


Dr. Palfreyman will also continue to serve as President at Palfreyman BioPharm Advisors, Inc. and as Board Member at Ophthakem and Amakem, both clinical stage companies targeting ocular disorders. He formerly held the position as VP of Development at EnVivo Pharmaceuticals, a company developing treatments for neurodegenerative disorders. Before this, Michael was Co-Founder, President and CSO of Psychiatric Genomics which focused on the discovery and development of novel drug treatments for mental illnesses. From 1994 until 2000 Michael served as SVP R&D at Scriptgen (Anadys) Pharmaceuticals. For 19 years prior to joining Scriptgen, he was VP and Senior Executive of the Research and Development Management Team at Marion Merrell Dow (now: Sanofi-Aventis).

Dr. Palfreyman holds a Bachelor’s degree in Pharmacy, a PhD in Neurobiology and Neurosciences, and a Doctor of Science in Rational Drug Design from the University of Nottingham.

“Michael adds an impressive industry background and deal experience to our team. I have known Michael for more than 10 years from interactions in different functions and settings. Working with him has always been extremely pleasant and rewarding.”, says Uwe Peukert, one of ActeaVentures’ Managing Partners. “We are thrilled to have him on board and we look forward to making his unique expertise and skill set available to our clients.”

About ActeaVentures

ActeaVentures is a global business development advisory firm for the Life Sciences Industry with operations in Europe, Asia and the US. With offices in Berlin, Boston, Karlsruhe, Lyon, Madrid, San Francisco, Shanghai and Singapore, ActeaVentures offers its clients comprehensive services for licensing and M&A projects in Pharma, Biotech, Diagnostics and Medtech. ActeaVentures’ team consists of Senior Business Development professionals with strong track records in deal making, having successfully served big pharma, medium-sized and biotech companies. ActeaVenturs GmbH ( is privately held and registered in Karlsruhe, Germany.